Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 23, 2010

Evotec and Merck KGaA Sign Neurological Drug Discovery Deal

  • Evotec and Merck KGaA inked a collaboration focused on the discovery and development of preclinical candidates against an undisclosed neurological disease. The collaboration comes under the auspices of the German government-funded Neu2 consortium, in which both firms are involved. It will be partially funded by the German Federal Ministry of Education and Research (BMBF).

    Established as part of the German Government’s BioPharma initiative to promote industry-academia partnerships, the Neu2 consortium aims to develop new treatments against multiple sclerosis and other neurological diseases. Under terms of the drug discovery deal with Merck, Evotec will provide drug discovery expertise in the areas of in vitro biology, medicinal chemistry and in vitro and in vivo pharmacology.

    Evotec has previously received stand-alone funding from the BMBF as part of the Neu2 program. In April the firm was awarded a potentially €1.5 million (about $1.99 million at the time) grant to fund its H3 receptor antagonist through Phase I trials. In November 2009 Evotec received a research grant of up to €2.5 million (about $3.74 million) to fund R&D on serine racemase, a potential target in the field of neuroprotection.

    Headed by Bionamics, the Neu2 consortium was established as one of the winners of Germany’s BioPharma Competition launched in 2007. The other two winning initiatives were the Max Planck Drug Discovery & Development Center and the Neuroallianz consortium. The BMBF has pledged to make €100 million in funding available to the three projects through to 2012. In the first round, the teams each received €20 million.

     

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »